Llovet J M , et al. Sorafenib in Advanced Hepatocellular Carcinoma.[J]. N Emgl J Med. 2008; 359:378-390.
doi: 10.1159/000503032
pmid: 31799207
[2]
Bruix J , et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.[J]. J Clin Oncol. 2017; 389:56-66.
doi: 10.1016/S0140-6736(16)32453-9
pmid: 27932229
[3]
Abou-Alfa G. K , et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.[J]. N Engl J Med. 2018; 379:54-63.
doi: 10.1056/NEJMoa1717002
pmid: 29972759
